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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess and summarize the effects of the MVA85A vaccine boosting BCG in humans.
B A C K G R O U N D
Description of the condition
Tuberculosis is an infectious disease caused by Mycobacterium tu-
berculosis. In 2016, 6.3 million new cases of tuberculosis were re-
ported. Tuberculosis now ranks first, followed by human immun-
odeficiency virus (HIV), as the leading cause of death from an in-
fectious disease worldwide killing an estimated 1.8 million people
in 2016, including 370,000 people living with HIV. Over 95%
of these people were living in low- and middle-income countries
(WHO 2017).
Tuberculosis can be classed as active when people experience signs
or symptoms of tuberculosis or have radiological evidence of it.
Tuberculosis can also be classified as latent tuberculosis infection
(LTBI) where immunological evidence of previous exposure to M.
tuberculosis exists without clinical or radiological evidence of the
disease (CDC 2000). Of healthy adults with immunological evi-
dence of previous exposure to M. tuberculosis, the overall lifetime
risk of progressing to active disease if not treated for the infec-
tion is 5% to 10% (Harries 2006). Often this happens months
or years after the initial infection in response to a weakening of
the body’s immune system. The probability of developing active
disease is higher in HIV-positive, diabetic patients, and young
children (Baker 2011; Perez-Velez 2012; Tiemersma 2010). Fifty
percent of infants with evidence of LTBI will progress to active
disease if untreated (Marais 2004). People with LTBI require early
diagnosis and treatment to reduce the pool of active tuberculosis
cases. This is particularly important in high-risk groups, such as
those co-infected with HIV (Sharma 2012). Tuberculosis can be
treated with long courses of multiple antibiotics, but the rise of
HIV and spread of multi-drug resistant tuberculosis (MDR-TB)
means that tuberculosis is still one of the largest threats to pub-
lic health worldwide (WHO 2017). Structural determinants such
as rapid urbanization of populations and economic inequalities,
social determinants such as poverty and poor housing, alongside
biological factors such as HIV and drug-resistant strains of tuber-
culosis play a vital role in the spread of tuberculosis through vul-
nerable populations (Daftary 2012).
The Bacillus Calmette-Guérin (BCG) vaccine is currently the only
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available vaccine. Epidemiological studies indicate that it has a pro-
tective effect against tuberculosis disease in children, particularly
against the more severe forms of the disease such as tuberculosis
meningitis or miliary tuberculosis (Roy 2014). The effectiveness
of BCG differs greatly depending on location and site of infec-
tion. It has consistent protection against tuberculosis meningitis
and miliary disease in children but variable protection against pul-
monary tuberculosis (Abubakar 2013; Colditz 1995). As a result,
despite many areas achieving high coverage of BCG vaccination,
the disease remains a problem, and a new tuberculosis vaccine re-
mains an important global research priority (WHO 2017).
Previously it has been impossible to ascertain reliably whether the
BCG vaccine protected against active disease or infection with M.
tuberculosis. This was due to the tuberculin skin test being unable
to distinguish between cases of LTBI and people who had been
vaccinatedwith BCG (Roy 2014). An important developmentwas
therefore the development and use of interferon gamma release
assays (IGRA), which can distinguish between tuberculosis infec-
tion and vaccination. This has allowed researchers to establish that
BCG vaccination reduces the risk of Mycobacterium infection in
some settings (Eisenhut 2009).
Description of the intervention
Many researchers and policymakers emphasize that a new effective
vaccine could be a major contribution to tuberculosis control and
elimination as a public health problem (de Cassan 2010). There
are 13 vaccine candidates in clinical trials: nine in Phase II or
Phase III, and four in Phase I. They include candidates to prevent
the development of tuberculosis, and candidates to help improve
the outcomes of treatment for tuberculosis disease (WHO 2017;
Table 1).
The modified Vaccinia Ankara virus expressing antigen 85A
(MVA85A) is a viral vector vaccine. It is based on the modified
Vaccinia Ankara (MVA) virus used as a vector. MVA is an attenu-
ated virus that does not replicate in human tissue and, as such, has
been used as a platform to encode multiple antigens and allow-
ing development of multivalent vaccines (Altenburg 2014). In this
case, MVA has had pieces of DNA from M. tuberculosis inserted
into it, so that it expresses the antigen 85A. This antigen complex
is an enzyme that is involved in the cell wall biosynthesis of M.
tuberculosis and constitutes a vital part of the way in which the
bacteria forms its outer mycomembrane. This is important for the
viability of the mycobacterium and works as an effective barrier to
drug therapies by repelling some antibiotics and preventing them
from entering the cell (Favrot 2013).
Immunological studies have shown that a prime boost strategy,
where MVA85A is used to boost the effects of BCG, is effective in
expanding immune responses specific toM. tuberculosis (Beveridge
2007). Thus MVA85A was proposed primarily as a booster to
individuals already vaccinated with BCG (Tameris 2013). Further
studies have also assessed MVA85A in other regimens including
in combination with other viral vector vaccines (Sheehan 2015).
How the intervention might work
MVA85A is the first vaccine since 1968 to be tested in efficacy trials
(Tameris 2013). It has been tried with a promise of prolonged an-
timycobacterial immunity in human UK trials (McShane 2004),
and in tuberculosis-endemic areas (Hawkridge 2008). The inten-
tion is that MVA85A would boost the immune response to tu-
berculosis above that which is afforded by vaccination with BCG
(Roy 2014). MVA85A is administered as a single intradermal dose
in people who have already received BCG vaccine (Tameris 2013).
Other routes have been studied in animal studies, such as aerosol
and intravenous administration (Kashangura 2015), and are being
considered in humans (Satti 2014).
The researchers who developed the vaccine have evaluated its ef-
fects in animals and conducted Phase 1 studies in humans. Early
literature and reviews by the team noted the vaccine was safe
and produced an immune response in a number of populations
(McShane 2004; Rowland 2012).
An independent systematic review of the animal studies, carried
out by some members of this Cochrane Review team, raised ques-
tions about whether these animal studies provided evidence of effi-
cacy in the various animal models used (Kashangura 2015), when
clinical and pathological endpoints were examined in a variety of
animal models subjected to challenge studies. These studies gave
BCG, BCG and MVA85A, or no vaccine and exposed animals to
tuberculosis challenge. Clearly progression to clinical trial is not
solely based on evidence derived from preclinical efficacy stud-
ies, but preclinical studies are an important component of the tu-
berculosis vaccine development paradigm (McShane 2014 Barker
2012).
The safety of the vaccine in human subjects has been evaluated in
a number of Phase 1 studies. The standard approach for Cochrane
Reviews within the Cochrane Infectious Diseases Group is to only
summarize efficacy trials. Given the interest over the balance be-
tween benefits and harms, we thought it helpful to summarize the
considerable number of Phase 1 studies that the researchers carried
out to exclude severe adverse effects attributable to the vaccine
in humans, and summarize the data from Phase 1 studies in this
Background section. We searched registered clinical trial databases
(ClinicalTrials.gov, WorldHealth Organiziation (WHO) Interna-
tional Clinical Trials Registry Platform (ICTRP), Pan African Tri-
als Registry, EUClinical Trials Register) in June 2017 and summa-
rized the Phase 1 studies identified in Table 2. We found 21 sepa-
rate studies as registered (prospectively and retrospectively) dating
from 2003 with the most recent studies scheduled to complete
follow-up in 2018. In addition, we found an existing narrative re-
view of Phase 1 studies (Rowland 2012), which summarizes Phase
1 safety data relating to selected trials including unpublished data
and compares this to selected trials in yellow fever and BCG.
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The 21 studies included 712 participants investigated from 2002
with follow-up expected to be completed by 2018. The studies
covered a diverse population in theUK, South Africa, Senegal, and
The Gambia with HIV-positive and HIV-negative individuals as
well as infants, children, and adults. Intramuscular, intradermal,
and aerosolized delivery routes were all investigated. The summary
shows most of the adverse events related to vaccination were mild
and were contained locally to the injection site. There were very
few serious adverse events; erythema and mild pain were the most
common.
Why it is important to do this review
Summarizing the evidence to date will be useful to the public, sci-
entists, and to others interested in innovation in tuberculosis. As of
November 2017, there are ongoing studies looking at aerosolized
delivery of the vaccine (NCT02532036). In 2017 studies have
been published that address the immunogenicity of what the study
authors termed “the candidate TB vaccine MVA85A” in Schistoso-
miasis-infected teenagers (Wajja 2017), and a further efficacy study
in HIV-exposed infants (Nemes 2017). This Cochrane Review
will help maintain a summary of various patient groups, routes,
and purposes for which the vaccine is being evaluated.
O B J E C T I V E S
To assess and summarize the effects of theMVA85A vaccine boost-
ing BCG in humans.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) that include measures of
clinical efficacy (Phase II clinical trials).
Types of participants
Any person regardless of age or HIV status.
Types of interventions
Intervention
MVA85A vaccine regardless of vaccination schedule, dosage,
route, or formulation given with BCG.
Control
BCG alone.
Types of outcome measures
Primary outcomes
Active tuberculosis, defined by either:
• clinical signs and symptoms fulfilling an algorithm defined
in the trial;
• clinical signs and symptoms plus confirmation by
microscopy, culture, or GeneXpert®;
• clinical signs and symptoms plus radiological evidence of
tuberculosis as defined in the trial.
Secondary outcomes
Latent tuberculosis, diagnosed by IGRA orMantoux without clin-
ical or radiological evidence of active disease.
Adverse outcomes
Adverse effects of any severity, defined as “an adverse event for
which the causal relation between the intervention and the event
is at least a reasonable possibility” (Loke 2011).
Serious adverse effects, defined as an adverse event attributable to
the intervention “leading to death, are life threatening, requires
inpatient hospitalisation or prolongation of existing hospitalisa-
tion, or result in persistent or significant disability or incapacity”
(ICH 1994).
Adverse events of any severity, defined as “any untoward medical
occurrence that may present during treatment with a pharmaceu-
tical product but which does not necessarily have a causal relation-
ship with this treatment” (WHO-ART 2008).
Abnormal haematological tests during the follow-up period after
being vaccinated.
Abnormal biochemical tests during the follow-up period after be-
ing vaccinated.
Search methods for identification of studies
We will attempt to identify all potential studies regardless of lan-
guage or publication status (published, unpublished, in press, and
in progress).
3MVA85A vaccine to enhance BCG for preventing tuberculosis (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Electronic searches
We will search the following databases using the search terms and
strategy described in Appendix 1: the Cochrane Infectious Dis-
eases Group Specialized Register; Central Register of Controlled
Trials (CENTRAL), published in the Cochrane Library; MED-
LINE (Pubmed); Embase (OVID); Science Citation Index-Ex-
panded, Social Sciences Citation index, Conference proceedings
(Web of Science); and CINAHL (EBSCOHost). We will also
search the WHO ICTRP (www.who.int/ictrp/en/) and Clinical-
Trials.gov (https://clinicaltrials.gov/ct2/home), using the search
terms:MVA85A, “modified vaccinia virusAnkara”, Ag85A , “Anti-
gen 85A”, and tuberculosis ORTBORBCG. If trials are reported
as completed in a trial registry and data are not in the public do-
main within two years of the last patient last visit (LPLV) we will
contact the authors to ask when the data will be available.
Searching other resources
We will search the proceedings and abstracts of the following tu-
berculosis conferences: UnionWorldConference on LungHealth,
European Respiratory Society, and the International Conference
of the American-Thoracic-Society (ATS), for the past five years.
We will handsearch reference lists of relevant papers, and contact
researchers working in the field.
Data collection and analysis
Selection of studies
Two review authorswill independently screen all abstracts retrieved
by the search strategy above using predefined eligibility criteria
designed and piloted by the review authors.We will exclude clearly
irrelevant studies. We will search for multiple publications using
studies from the same data set. Full-text copies will be retrieved
for all trials thought to be potentially relevant. Two review authors
will then independently assess all identified trials for inclusion in
the review using the pre-defined inclusion criteria.
We will resolve any disagreements in assessment through discus-
sion. In cases of unresolved differences, a third review author will
adjudicate. We will keep records of the initial results and the
changes after discussion. We will list all studies excluded after full-
text assessment in a ’Characteristics of excluded studies’ table. We
will illustrate the study selection process in a PRISMA diagram.
Data extraction and management
We will design and pilot data extraction forms. Data extraction
and management will be done independently and in duplicate.
We will gather information from each included trial separately on
trial characteristics. This will include:
• study setting, design, study duration, population sample
size, and power calculations;
• baseline characteristics of study population including age,
sex, weight, prematurity, HIV, other comorbidity, whether
breastfeeding,race, HIV status, antiretroviral therapy (ART),
CD4 count, and viral load;
• the intervention and control group vaccine dosages, routes
of administration, and times of vaccination;
• time of outcome measure after administering MVA85A;
• duration of follow-up, any participants who withdrew from
the study, and reasons why.
All outcomes are dichotomous so we will tabulate numbers of par-
ticipants who developed tuberculosis disease or an adverse event
(n) with the total sample size number (N) in each of the compar-
ison groups. We will document the different definitions of out-
comes in the trials for further consideration.
Two review authors will compare data extracted and resolve dis-
crepancies through discussion with a third review author. We will
later combine the separate reports on a multiple data collection
sheet including key elements of each study. We will then transfer
this information to Review Manager 5 (RevMan 5) for analysis
(RevMan 2014). Authors of included studies will be contacted for
missing information and any other queries.
Three review authors (RK, SoJ, and SaJ) will screen studies, design,
and pilot extraction forms and extract data.
Assessment of risk of bias in included studies
Wewill assess the study quality for RCTs using the Cochrane ’Risk
of bias’ tool (Higgins 2011).
All studies will be assessed for risk of bias independently and in
duplicate. We will resolve any disagreement through discussion
and, where necessary, through consultation with a third review
author.
Two review authors will initially pilot the ’Risk of bias’ assessments
on four included trials to check for consistency and to ensure all
methodological issues have been understood. Sequence generation
(if predictable method used) and allocation concealment will as-
sess for selection bias and detection bias will be assessed by look-
ing at blinding methods. We will consider both the intention of
blinding and the success of blinding for each outcome. If there is
no description of the procedure, for example how randomization
was done, we will mark it as unclear.
In addition, we will examine the objectivity of outcome measures,
use of intention-to-treat (ITT) analysis, loss to follow-up, and
selective outcome reporting in order to assess the risk of bias in
included studies. We will also assess whether outcome measures
are specified a priori and whether the published endpoints match
those specified in study protocols.
We will assess incomplete outcome data in each included trial to
determine the proportion of missing results and whether it affects
the results or not in terms of event risk and effect size. We will
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assess if reasons for missing data are related to adverse events or
death from MVA85A and if missing data balanced in the two
experimental groups in order to have an overall decision on risk
associated with incomplete outcome data.
Other forms of high risk of bias will include influence by funders,
extreme differences in baseline characteristics, and stopping of the
trial before it is finished for unclear reasons.
For adverse effects and events we will use methods used in pre-
vious systematic reviews, as outlined in Table 3. We will assess
the included trials for risk of bias by examining if monitoring
was active or passive; whether participants and outcome assessors
were blinded; whether the outcome data reporting was complete;
whether all participants were included; and whether data analysis
was independent of pharmaceutical companies (Bukirwa 2014).
If there is insufficient information to assess risk of bias we will
contact authors to obtain information needed to adequately assess
risk of bias.
Measures of treatment effect
We will analyse all data using RevMan 5 (RevMan 2014). If ap-
propriate, we will present and combine dichotomous data using
risk ratios (RR) with their corresponding 95% confidence inter-
vals (CI); and we will express continuous outcomes as standard-
ized mean differences with 95% CIs.
Unit of analysis issues
If we identify studies for inclusion that have multiple intervention
arms, we will include data from these studies by either combining
treatment arms, or by splitting the control group so that partici-
pants are only included in the meta-analysis once.
Where studies undertook multiple observations on the same par-
ticipants we will stratify the analysis by time point.
Dealing with missing data
We will assess missing data to see if it is related to outcome. If
missing data from trial reports restricts the use of the study, we will
contact trial authors formore information. It is anticipated that for
older publications it may not be possible to reach the trial author.
If data are missing at random, we will analyse only the available
data. If the amount of incomplete outcome data is such that the
trial is thought to be at a high risk of bias, we may use imputation
and perform sensitivity analyses to investigate the impact of this
missing data.
We will use ITT analysis for all outcomes except adverse effects
where a treatment received analysis will be done.
Assessment of heterogeneity
Wewill assess extracted data from included trials to find key differ-
ences in population groups, study setting, intervention and con-
trol groups, dosages and route of vaccine administration, or timing
between BCG and boosting. Degree of risk of bias, when and how
the outcome was measured, and variation in treatment effects will
also be assessed.
We will determine the level of heterogeneity by inspecting forest
plots for overlapping CIs. We will judge a Chi² P value signifi-
cance level of ≤ 0.1 as likely heterogeneity. An I2 statistic value
of less than 40% will be regarded as not showing any significant
heterogeneity.
Assessment of reporting biases
If applicable, we will use funnel plot analysis or statistical tests
such as an Egger regression test, or both, to assess for publication
bias.
Data synthesis
Wewill use the fixed-effectMantel-Haenszel model for meta-anal-
ysis. The intention for meta-analysis of adverse outcomes will be
to limit it to three to five of the most frequent adverse effects and
all those that were considered to be serious. However, due to dif-
ferent methods of monitoring adverse effects that in turn lead to
different results, meta-analysis might not be done and a narrative
report given instead.
If appropriate, we will perform statistical adjustments for sample
size and variance for any cluster randomized trials before meta-
analysis according tomethods described in theCochrane Handbook
for Systematic Review of Interventions (Higgins 2011).
Subgroup analysis and investigation of heterogeneity
We will explore heterogeneity by:
• subgroup by children and adults;
• background prevalence of tuberculosis (or tuberculosis
incidence in the control group);
• HIV status; and
• geographical location.
We will consider random-effects meta-analysis if subgroup analy-
sis does not explain the heterogeneity. The I² statistic will be ap-
plied according to guidance of: less than 40% as not significant
heterogeneity; 30% to 60% representing moderate heterogeneity;
50% to 90% representing substantial heterogeneity; and 75% to
100% considerable heterogeneity (Higgins 2011). We will regard
a Chi² P value significance level of ≤ 0.1 and an I² statistic value
of > 40% as showing significant heterogeneity, in which case we
will either consider a random-effects model or we will not per-
form meta-analysis. In case of extensive qualitative heterogeneity,
we will not carry out meta-analysis.
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We will report the term used for any adverse effect in each trial.
Where trials use different terminology for similar adverse events
and adverse effects, we will code them using the preferred term
based onMedical Dictionary for Regulatory Activities (MedDRA)
terminology (for example, sleepiness, somnolence) and analyse
them together (MedDRA 2016).
Sensitivity analysis
Wewill perform sensitivity analysis for imputed data and any other
peculiarities between the trials identified during the review process
If high risk of bias is identified in some trials, we will perform
sensitivity analysis by assessing results after excluding trials that are
at high or unclear risk of bias. Methodological quality summaries
will show review author judgements about each ’Risk of bias’ as-
sessment item for each included trial and also weighting of each
item across all included trials.
Certainty of the evidence
We will assess the certainty of the evidence using the GRADE
approach (Langer 2012). We will construct a ‘Summary of find-
ings’ table, which will show themain review findings for outcomes
listed under the ’Types of outcome measures’ section.
A C K N OW L E D G E M E N T S
The review author team and the editorial base of the Cochrane
Infectious Diseases Group are supported by the Effective Health
Care ResearchConsortium. This Consortium is funded byUK aid
from the UK Government for the benefit of developing countries
(Grant: 5242). The views expressed in this publication do not
necessarily reflect UK government policy.
R E F E R E N C E S
Additional references
Abubakar 2013
Abubakar I, Pimpin L, Ariti C, Beynon R, Mangtani P,
Sterne JA, et al. Systematic review and meta-analysis of the
current evidence on the duration of protection by bacillus
Calmette-Guérin vaccination against tuberculosis. Health
Technology Assessment 2013;17(37):1-372, v-vi.
Altenburg 2014
Altenburg AF, Kreijtz JH, de Vries RD, Song F, Fux R,
Rimmelzwaan GF, et al. Modified vaccinia virus ankara
(MVA) as production platform for vaccines against influenza
and other viral respiratory diseases. Viruses 2014;6(7):
2735–61.
Baker 2011
Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A,
Lönnroth K, et al. The impact of diabetes on tuberculosis
treatment outcomes: a systematic review. BMC Medicine
2011;9:81.
Barker 2012
Barker L, Hessel L, Walker B. Rational approach to selection
and clinical development of TB vaccine candidates.
Tuberculosis 2012;92(Suppl 1):S25–9.
Beveridge 2007
Beveridge NE, Price DA, Casazza JP, Pathan AA, Sander
CR, Asher TE, et al. Immunisation with BCG and
recombinant MVA85A induces long-lasting, polyfunctional
Mycobacterium tuberculosis-specific CD4+ memory T
lymphocyte populations. European Journal of Immunology
2007;37(11):3089–100.
Brookes 2008
Brookes RH, Hill PC, Owiafe PK, Ibanga HB, Jeffries
DJ, Donkor SA, et al. Safety and immunogenicity of the
candidate tuberculosis vaccine MVA85A in West Africa.
PLoS One 2008;3(8):e2921.
Bukirwa 2014
Bukirwa H, Unnikrishnan B, Kramer CV, Sinclair D, Nair
S, Tharyan P. Artesunate plus pyronaridine for treating
uncomplicated Plasmodium falciparum malaria. Cochrane
Database of Systematic Reviews 2014, Issue 3. [DOI:
10.1002/14651858.CD006404.pub2
CDC 2000
Centers for Disease Control and Prevention. Diagnostic
Standards and Classification of Tuberculosis in Adults and
Children. This official statement of the American Thoracic
Society and the Centers for Disease Control and Prevention
was adopted by the ATS Board of Directors, July 1999. This
statement was endorsed by the Council of the Infectious
Disease Society of America. American Journal of Respiratory
and Critical Care Medicine 2000;161(4 Pt 1):1376–95.
Colditz 1995
Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson
ME, Burdick E, et al. The efficacy of bacillus Calmette-
Guérin vaccination of newborns and infants in the
prevention of tuberculosis: meta-analyses of the published
literature. Paediatrics 1995;96(1 Pt 1):29–35.
Daftary 2012
Daftary A, Padayatchi N. Social constraints to TB/HIV
healthcare: accounts from coinfected patients in South
Africa. AIDS Care 2012;24(12):1480–6.
de Cassan 2010
de Cassan SC, Pathan AA, Sander CR, Minassian A,
Rowland R, Hill AV, et al. Investigating the induction of
vaccine-induced Th17 and regulatory T cells in healthy,
Mycobacterium bovis BCG-immunized adults vaccinated
6MVA85A vaccine to enhance BCG for preventing tuberculosis (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
with a new tuberculosis vaccine, MVA85A. Clinical and
Vaccine Immunology 2010;17(7):1066–73.
Dieye 2013
Dieye TN, Ndiaye BP, Dieng AB, Fall M, Brittain N,
Vermaak S, et al. Two doses of candidate TB vaccine
MVA85A in antiretroviral therapy (ART) naïve subjects
gives comparable immunogenicity to one dose in ART+
subjects. PLoS One 2013;8(6):e67177.
Eisenhut 2009
Eisenhut M, Paranjothy S, Abubakar I, Bracebridge S, Lilley
M, Mulla R, et al. BCG vaccination reduces risk of infection
with Mycobacterium tuberculosis as detected by gamma
interferon release assay. Vaccine 2009;27(44):6116–20.
Favrot 2013
Favrot L, Grzegorzewicz AE, Lajiness DH, Marvin RK,
Boucau J, Isailovic D, et al. Mechanism of inhibition
of Mycobacterium tuberculosis antigen 85 by ebselen.
Nature Communications 2013;4:2748. [DOI: 10.1038/
ncomms3748
Griffiths 2011
Griffiths KL, Pathan AA, Minassian AM, Sander CR,
Beveridge NE, Hill AV, et al. Th1/Th17 cell induction and
corresponding reduction in ATP consumption following
vaccination with the novel Mycobacterium tuberculosis
vaccine MVA85A. PLoS One 2011;6(8):e23463.
Harries 2006
Harries AD, Dye C. Tuberculosis. Annals of Tropical
Medicine and Parasitology 2006;100(5-6):415–31.
Harris 2014a
Harris SA, Meyer J, Satti I, Marsay L, Poulton ID, Tanner
R, et al. Evaluation of a human BCG challenge model to
assess antimycobacterial immunity induced by BCG and
a candidate tuberculosis vaccine, MVA85A, alone and in
combination. Journal of Infectious Diseases 2014;209(8):
1259–68.
Harris 2014b
Harris SA, Satti I, Matsumiya M, Stockdale L, Chomka A,
Tanner R, et al. Process of assay selection and optimization
for the study of case and control samples from a phase IIb
efficacy trial of a candidate tuberculosis vaccine, MVA85A.
Clinical and Vaccine Immunology 2014;21(7):1005–11.
Hawkridge 2008
Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris
M, Moyo S, et al. Safety and immunogenicity of a new
tuberculosis vaccine, MVA85A, in healthy adults in South
Africa. Journal of Infectious Diseases 2008;198(4):544–52.
[DOI: 10.1086/590185
Higgins 2011
Higgins JPT, Green S, editor(s). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0
(updated March 2011). The Cochrane Collaboration,
2011. Available from handbook.cochrane.org. Chichester
(UK): Available from www.handbook.cochrane.org..
Ibanga 2006
Ibanga HB, Brookes RH, Hill PC, Owiafe PK, Fletcher
HA, Lienhardt C, et al. Early clinical trials with a new
tuberculosis vaccine, MVA85A, in tuberculosis-endemic
countries: issues in study design. Lancet. Infectious Diseases
2006;6(8):522–8.
ICH 1994
International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use (ICH). Clinical safety data management:
definitions and standards for expedited reporting E2A.1994.
ICH harmonised tripartite guideline. Current Step 4
version dated 27 October 1994. www.ich.org/fileadmin/
Public Web Site/ICH Products/Guidelines/Efficacy/E2A/
Step4/E2A Guideline.pdf (accessed 23 August 2017).
Kashangura 2015
Kashangura R, Sena ES, Young T, Garner P. Effects of
MVA85A vaccine on tuberculosis challenge in animals:
systematic review. International Journal of Epidemiology
2015;44(6):1970–81. [DOI: 10.1093/ije/dyv142
Langer 2012
Langer G, Meerpohl JJ, Perleth M, Gartlehner G, Kaminski-
Hartenthaler A, Schunemann H. GRADE guidelines: 1.
Introduction - GRADE evidence profiles and summary of
findings tables. Zeitschrift für Evidenz, Fortbildung und
Qualitat im Gesundheitswesen 2012;106(5):357–68.
Lefebvre 2011
Lefebvre C, Manheimer E, Glanville J. Chapter 6:
Searching for studies. In: Higgins JP, Green S, editor
(s). Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0 (updated March 2011).
The Cochrane Collaboration, 2011. Available from
handbook.cochrane.org. The Cochrane Collaboration,
2011. Available from www.cochrane–handbook.org..
Loke 2011
Loke YK, Price D, Herxheimer A. Chapter 14: Adverse
effects. In: Higgins JP, Green S, editor(s). Cochrane
Handbook for Systematic Reviews of Interventions Version
5.1.0 (updated March 2011). The Cochrane Collaboration,
2011. Available from handbook.cochrane.org. The
Cochrane Collaboration, 2011. Available at www.cochrane–
handbook.org, 2011..
Manjaly Thomas 2016
Manjaly Thomas ZR, Satti I, Wilkie M, Harris S, Riste
M, Hamidi A, et al. A Phase I Trial Evaluating Aerosol
Administration of a Candidate TB Vaccine, MVA85A, as a
Way to Induce Potent Local Cellular Immune Responses
and Avoid Anti-Vector Immunity. American Thoracic
Society 2016 International Conference, 2016 May 13-
8; San Francisco (CA). American Journal of Respiratory
and Critical Care Medicine 2016;193(Meeting Abstracts):
A5487.
Marais 2004
Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC,
Starke JJ, et al. The natural history of childhood intra-
thoracic tuberculosis: a critical review of literature from the
pre-chemotherapy era. International Journal of Tuberculosis
and Lung Disease 2004;8(4):392–402.
7MVA85A vaccine to enhance BCG for preventing tuberculosis (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Matsumiya 2013
Matsumiya M, Stylianou E, Griffiths K, Lang Z, Meyer J,
Harris SA, et al. Roles for Treg expansion and HMGB1
signaling through the TLR1-2-6 axis in determining the
magnitude of the antigen-specific immune response to
MVA85A. PLoS One 2013;8(7):e67922.
McShane 2004
McShane H, Pathan AA, Sander CR, Keating SM, Gilbert
SC, Huygen K, et al. Recombinant modified vaccinia virus
Ankara expressing antigen 85A boosts BCG-primed and
naturally acquired antimycobacterial immunity in humans.
Nature Medicine 2004;10(11):1240–4.
McShane 2014
McShane H, Williams A. A review of preclinical animal
models utilised for TB vaccine evaluation in the context
of recent human efficacy data. Tuberculosis 2014;94(2):
105–10.
MedDRA 2016
International Federation of Pharmaceutical Manufacturers
and Associations. Medical dictionary for regulatory
activities. Version 19.0. www.meddra.org/news-and-
events/news/english-meddra-version-201-now-available-
download) (accessed 23 August 2017).
Meyer 2013
Meyer J, Harris SA, Satti I, Poulton ID, Poyntz HC,
Tanner R, et al. Comparing the safety and immunogenicity
of a candidate TB vaccine MVA85A administered by
intramuscular and intradermal delivery. Vaccine 2013;31
(7):1026–33.
Minassian 2011
Minassian AM, Rowland R, Beveridge NE, Poulton ID,
Satti I, Harris S, et al. A Phase I study evaluating the safety
and immunogenicity of MVA85A, a candidate TB vaccine,
in HIV-infected adults. BMJ Open 2011;1(2):e000223.
Minhinnick 2016
Minhinnick A, Satti I, Harris S, Wilkie M, Sheehan
S, Stockdale L, et al. A first-in-human phase 1 trial to
evaluate the safety and immunogenicity of the candidate
tuberculosis vaccine MVA85A-IMX313, administered to
BCG-vaccinated adults. Vaccine 2016;34(11):1412–21.
NCT00395720
NCT00395720. The safety and immunogenicity of a TB
vaccine; MVA85A, in healthy volunteers who are infected
with HIV [A Phase I study evaluating the safety and
immunogenicity of a new TB vaccine, MVA85A, in healthy
volunteers who are infected with HIV]. clinicaltrials.gov/
ct2/show/NCT00395720 (first received 25 August 2017).
NCT00423566
NCT00423566. A Phase I study of the safety and
immunogenicity of a recombinant MVA vaccine encoding
a secreted antigen from M. tuberculosis, antigen 85A,
delivered intradermally by a needle injection in healthy
volunteers. clinicaltrials.gov/ct2/show/NCT00423566
(first received 25 August 2017).
NCT00423839
NCT00423839. A Phase I study of the safety and
immunogenicity of MVA85A in healthy Gambian
volunteers. clinicaltrials.gov/ct2/show/NCT00423839
(first received 25 August 2017).
NCT00427453
NCT00427453. A Phase I study of the safety and
immunogenicity of a recombinant MVA vaccine encoding
a secreted antigen from M. tuberculosis, antigen 85A,
delivered intradermally by a needle injection in healthy
volunteers who have received BCG immunisation 1 month
previously. clinicaltrials.gov/ct2/show/NCT00427453 (first
received 25 August 2017).
NCT00427830
NCT00427830. A Phase I study of the safety and
immunogenicity of a recombinant MVA vaccine encoding
a secreted antigen from M. tuberculosis, antigen
85A, delivered intradermally by a needle injection in
healthy volunteers who have previously received BCG.
clinicaltrials.gov/ct2/show/NCT00427830 (first received
25 August 2017).
NCT00456183
NCT00456183. Safety and immunogenicity of MVA85A
in volunteers latently infected with TB. clinicaltrials.gov/
ct2/show/NCT00456183 (first received 25 August 2017).
NCT00460590
NCT00460590. Safety and immunogenicity of MVA85A,
in healthy volunteers in Cape Town. clinicaltrials.gov/ct2/
show/NCT00460590 (first received 25 August 2017).
NCT00465465
NCT00465465. A study of 2 doses of a new TB vaccine,
MVA85A, in healthy volunteers previously vaccinated with
BCG. clinicaltrials.gov/ct2/show/NCT00465465 (first
received 25 August 2017).
NCT00480454
NCT00480454. Safety, immunogenicity, and impact of
MVA85A, on the immunogenicity of the EPI vaccines.
clinicaltrials.gov/ct2/show/NCT00480454 (first received
25 August 2017).
NCT00480558
NCT00480558. A study of MVA85A, in asymptomatic
volunteers infected with TB, HIV or both. clinicaltrials.gov/
ct2/show/NCT00480558 (first received 25 August 2017).
NCT00548444
NCT00548444. T−Cell turnover following vaccination
with MVA85A. clinicaltrials.gov/ct2/show/NCT00548444
(first received 25 August 2017).
NCT00653770
NCT00653770. A Phase I study to assess the safety and
immunogenicity of tuberculosis (TB) vaccine candidates
FP85A and MVA85A. clinicaltrials.gov/ct2/show/
NCT00653770 (first received 25 August 2017).
NCT00731471
NCT00731471. A Phase I study of a new tuberculosis
(TB) vaccine, MVA85A, in healthy volunteers with HIV.
8MVA85A vaccine to enhance BCG for preventing tuberculosis (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
clinicaltrials.gov/ct2/show/NCT00731471 (first received
25 August 2017).
NCT01181856
NCT01181856. Safety of tuberculosis vaccine, MVA85A,
administered by the intramuscular route and the intradermal
route. clinicaltrials.gov/ct2/show/NCT01181856 (first
received 25 August 2017).
NCT01194180
NCT01194180. A BCG challenge model study to assess
anti-mycobacterial immunity induced by BCG and a
candidate TB vaccine, MVA85A. clinicaltrials.gov/ct2/
show/NCT01194180 (first received 25 August 2017).
NCT01497769
NCT01497769. Safety of tuberculosis vaccine, MVA85A,
administered by the aerosol route and the intradermal route.
clinicaltrials.gov/ct2/show/NCT01497769 (first received
25 August 2017).
NCT01683773
NCT01683773. Safety study of tuberculosis vaccines
AERAS-402 and MVA85A. clinicaltrials.gov/ct2/show/
NCT01683773 (first received 25 August 2017).
NCT01829490
NCT01829490. Safety study of ChAdOx185A vaccination
with and without MVA85A boost in healthy adults
[Phase 1 trial to evaluate the safety and immunogenicity
of a ChAdOx185A with or without MVA85A boost in
healthy BCG vaccinated adults]. clinicaltrials.gov/show/
NCT01829490 (first received 11 April 2013).
NCT01879163
NCT01879163. Phase I trial evaluating safety and
immunogenicity of MVA85A-IMX313 compared to
MVA85A in BCG vaccinated adults. clinicaltrials.gov/ct2/
show/NCT01879163 (first received 25 August 2017).
NCT01954563
NCT01954563. Study evaluating aerosol and intradermal
administration of a candidate tuberculosis (TB) vaccine,
MVA85A, as a way to increase immune response and
avoid anti-vector immunity. clinicaltrials.gov/ct2/show/
NCT01954563 (first received 25 August 2017).
NCT02532036
NCT02532036. MVA85A aerosol versus intramuscular
vaccination in adults with latent Mycobacterium
tuberculosis (M. tb) Infection [A phase I trial to compare
the safety and immunogenicity of candidate tuberculosis
vaccine MVA85A administered by the aerosol inhaled route
and the intramuscular route in healthy adult volunteers
who are latently infected with Mycobacterium tuberculosis].
clinicaltrials.gov/show/NCT02532036 (first received 25
August 2015).
Nemes 2017
Nemes E, Hesseling A, Tameris M, Mauff K, Downing
K, Mulenga H, et al. Safety and Immunogenicity of
Newborn MVA85A Vaccination and Selective, Delayed
Bacille Calmette-Guerin (BCG) for Infants of HIV Infected
Mothers: A Phase 2 Randomized Controlled Trial. Clinical
Infectious Diseases 2017 Sept 26 [Epub ahead of print].
[DOI: 10.1093/cid/cix834
Odutola 2012
Odutola AA, Owolabi OA, Owiafe PK, McShane H, Ota
MOC. A new TB vaccine, MVA85A, induces durable
antigen-specific responses 14 months after vaccination in
African infants. Vaccine 2012;30(38):5591–4.
Ota 2011
Ota MO, Odutola AA, Owiafe PK, Donkor S, Owolabi
OA, Brittain NJ, et al. Immunogenicity of the tuberculosis
vaccine MVA85A is reduced by coadministration with
EPIvaccines in a randomized controlled trial in Gambian
infants. Science Translational Medicine 2011;3(88):88ra56.
Owiafe 2012
Owiafe P, Hill P, Ibanga HB, Brookes RH, McShane H,
Sutherland JS, et al. Differential cytokine levels in adults
induced by a novel candidate TB boost vaccine, MVA85A-
according to previous BCG vaccination status. Journal of
Vaccines & Vaccination 2012;3(7):158.
Pathan 2007
Pathan AA, Sander CR, Fletcher HA, Poulton I, Alder NC,
Beveridge NE, et al. Boosting BCG with recombinant
modified vaccinia ankara expressing antigen 85A: different
boosting intervals and implications for efficacy trials. PLoS
One 2007;2(10):e1052.
Pathan 2012
Pathan AA, Minassian AM, Sander CR, Rowland R, Porter
DW, Poulton ID, et al. Effect of vaccine dose on the safety
and immunogenicity of a candidate TB vaccine, MVA85A,
in BCG vaccinated UK adults. Vaccine 2012;30(38):
5616–24.
Perez-Velez 2012
Perez-Velez CM, Marais BJ. Tuberculosis in children. New
England Journal of Medicine 2012;367(4):348–61.
RevMan 2014 [Computer program]
Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager 5 (RevMan 5). Version 5.3. Copenhagen:
Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Rowland 2012
Rowland R, Brittain N, Poulton ID, Minassian AM, Sander
C, Porter DW, et al. A review of the tolerability of the
candidate TB vaccine, MVA85A compared with BCG and
Yellow Fever vaccines, and correlation between MVA85A
vaccine reactogenicity and cellular immunogenicity. Trials
in Vaccinology 2012;1:27–35.
Rowland 2013
Rowland R, Pathan AA, Satti I, Poulton ID, Matsumiya
MM, Whittaker M, et al. Safety and immunogenicity of an
FP9-vectored candidate tuberculosis vaccine (FP85A), alone
and with candidate vaccine MVA85A in BCG-vaccinated
healthy adults: a phase I clinical trial. Human Vaccine
Immunotherapy 2013;9(1):50-62.
Roy 2014
Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar
S, Habermann S, et al. Effect of BCG vaccination
9MVA85A vaccine to enhance BCG for preventing tuberculosis (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
against Mycobacterium tuberculosis infection in children:
systematic review and meta-analysis. BMJ 2014;349:g4643.
[DOI: 10.1136/bmj.g4643
Sander 2009
Sander CR, Pathan AA, Beveridge NER, Poulton I,
Minassian A, Alder N, et al. Safety and Immunogenicity of
a New Tuberculosis Vaccine, MVA85A, in Mycobacterium
tuberculosis-infected Individuals. American Journal of
Respiratory and Critical Care Medicine 2009;179(8):724–33.
Satti 2014
Satti I, Meyer J, Harris SA, Manjaly Thomas ZR, Griffiths
K, Antrobus RD, et al. Safety and immunogenicity of
a candidate tuberculosis vaccine MVA85A delivered by
aerosol in BCG-vaccinated healthy adults: a phase 1,
double-blind, randomised controlled trial. Lancet. Infectious
Diseases 2014;14(10):939–46.
Scriba 2010
Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe
L, Isaacs F, et al. MVA85A, a novel TB vaccine, is safe
in adolescents and children, and induces complex subsets
of polyfunctional CD4+ T cells. European Journal of
Immunology 2010;40(1):279-90.
Scriba 2012
Scriba TJ, Tameris M, Smit E, van der Merwe L, Hughes
EJ, Kadira B, et al. A Phase IIa trial of the new tuberculosis
vaccine, MVA85A, in HIV- and/or Mycobacterium
tuberculosis-infected Adults. American Journal of Respiratory
and Critical Care 2012;185(7):769-78.
Sharma 2012
Sharma SK, Mohanan S, Sharma A. Relevance of latent TB
infection in areas of high TB prevalence. Chest 2012;142
(3):761–73.
Sheehan 2015
Sheehan S, Harris SA, Satti I, Hokey DA, Dheenadhayalan
V, Stockdale L, et al. A phase I, open-label trial, evaluating
the safety and immunogenicity of candidate tuberculosis
vaccines AERAS-402 and MVA85A, administered by
prime-boost regime in BCG-vaccinated healthy adults.
PLoS One 2015;10(11):e0141687.
Tameris 2013
Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden
MA, Lockhart S, et al. Safety and efficacy of MVA85A, a
new tuberculosis vaccine, in infants previously vaccinated
with BCG: a randomised, placebo-controlled phase 2b trial.
Lancet 2013;381(9871):1021–8.
Tameris 2014
Tameris M, Geldenhuys H, Luabeya AK, Smit E, Hughes
JE, Vermaak S, et al. The candidate TB Vaccine, MVA85A,
induces highly durable Th1 responses. PLoS One 2014;9
(2):e87340.
Tanner 2014
Tanner R, Kakalacheva K, Miller E, Pathan AA, Chalk
R, Sander CR, et al. Serum indoleamine 2,3-dioxygenase
activity is associated with reduced immunogenicity
following vaccination with MVA85A. BMC Infectious
Diseases 2014;14:660.
Tiemersma 2010
Tiemersma EW, van der Werf MJ, Borgdorff MW,Williams
BG, Nagelkerke NJ. Natural history of tuberculosis:
duration and fatality of untreated pulmonary tuberculosis
in HIV negative patients: a systematic review. PLoS One
2011;6:e17601.
Wajja 2017
Wajja A, Kizito D, Nassanga B, Nalwoga A, Kabagenyi
J, Kimuda S, et al. The effect of current Schistosoma
mansoni infection on the immunogenicity of a candidate
TB vaccine, MVA85A, in BCG-vaccinated adolescents: An
open-label trial. PLoS Neglected Tropical Diseases 2017;11
(5):e0005440.
Whelan 2009
Whelan KT, Pathan AA, Sander CR, Fletcher HA, Poulton
I, Alder NC, et al. Safety and immunogenicity of boosting
BCG vaccinated subjects with BCG: comparison with
boosting with a new TB Vaccine, MVA85A. PLoS One
2009;4(6):e5934.
WHO 2017
World Health Organization. Global Tuberculosis Report
2017. www.who.int/tb/publications/global report/en/
(accessed 13 December 2017).
WHO-ART 2008
Uppsala Monitoring Centre. WHO adverse reaction
terminology (WHO-ART). www.who-umc.org/vigibase/
services/learn-more-about-who-art/ (accessed 23 August
2017).
∗ Indicates the major publication for the study
A D D I T I O N A L T A B L E S
Table 1. Novel vaccines undergoing trials for tuberculosis prevention
Category Vaccine Clinical trial stage
Protein/adjuvant M72/AS01 Phase IIb
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Table 1. Novel vaccines undergoing trials for tuberculosis prevention (Continued)
H4/IC31 Phase IIa
H56/IC31 Phase IIa
ID93/GLA-SE Phase IIa
Viral vector MVA85A (Aerosol) Phase I
ChAdOx185A Phase I
Ad5Ag85A Phase I
TB FLu -04L Phase II
Live Mycobacteria MTBVAC Phase I
VPM1002 Phase IIb
Mycobacteria whole cell/extract Dar-901 booster Phase IIb
RUTI Phase IIa
Vaccae Phase III
Table adapted from WHO 2017.
Table 2. Summary of Phase 1 studies
NCT trial
number
Route Dates Inter-
vention and
schedule de-
tails
Country Participants
(age)
HIV Adverse events Reference
NCT00423566
ID 2002-3 MVA85A; 1
dose
UK 14 adults (18
to 45 years)
-ve 7 trials (112 par-
ticipants); com-
bined in one re-
port:
no serious AE at-
tributable to the
vaccine
McShane 2004,
Rowland 2012
NCT00423839
ID 2003-5 MVA85A; 1
dose, 2 doses
(5 x 107
PFU)
Gambia 21 adults N/R No serious AE at-
tributable to the
vaccine
Brookes 2008;
Ibanga 2006;
Owiafe 2012
NCT00427830
ID 2003-5 MVA85A; 1
dose (5 x 107
UK 21 adults -ve No serious AE at-
tributable to the
McShane 2004;
Pathan 2007;
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Table 2. Summary of Phase 1 studies (Continued)
PFU) vaccine Rowland 2012;
Tanner 2014;
Whelan 2009
NCT00427453
ID 2003-5 MVA85A; 1
dose (5 x 107
PFU)
UK 10 adults -ve No serious AE at-
tributable to the
vaccine
Pathan 2007;
Rowland 2012
NCT00456183
ID 2005-7 MVA85A, (5
x 107 PFU)
UK 12 adults
with latent
tuberculosis
-ve No vaccine re-
lated serious ad-
verse events
7 trials (112
participants; data
combined in one
report)
Rowland 2012;
Sander 2009;
Tanner 2014
NCT00465465
ID 2005-7 MVA85A; 1
dose (1 x 10
8 PFU for 12
participants,
and 1 x 10
7 PFU for 12
participants)
UK 24 adults -ve No serious AE at-
tributable to the
vaccine
Griffiths 2011;
Matsumiya
2013; Pathan
2012; Rowland
2012
NCT00460590
ID 2005-8 MVA85A, (5
x 107 PFU)
South Africa 36 adults and
adolescents
-ve No vaccine re-
lated serious ad-
verse events
Hawkridge
2008; Scriba
2010; Tameris
2014; Tanner
2014
NCT00480454
ID 2006-9 MVA85A;
1 dose
MVA85A (2.
5 x 107 PFU,
5 x 107 PFU)
Groups
1. EPI
vaccines:
2. MVA85A +
EPI:
3. MVA85A +
EPI 1 week
later
The Gambia 214 infants
(4 months)
N/R No serious AE
judged to be re-
lated to the vac-
cine
Odutola 2012;
Ota 2011
NCT00395720
ID 2006-10 MVA85A; 1
dose (5 x 10
7PFU for 10
UK 20 adults +ve No serious AE at-
tributable to the
vaccine
Minassian 2011
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Table 2. Summary of Phase 1 studies (Continued)
participants,
and 1 x 10
8 PFU for 10
participants)
NCT00480558
ID 2007-11 MVA85A; 1
dose (5 x 107
PFU)
4 groups
with back-
ground of
1. MTB
2. HIV
3. MTB +
HIV
4. HIV on
ART
South Africa 48 adults (18
to 50 years)
+ve No vaccine re-
lated serious ad-
verse effects
Scriba 2012;
Tanner 2014;
Tameris 2014
NCT00653770
ID 2007-10 FP85A,
MVA85A (5
x 107PFU)
UK 31 adults -ve No serious AE at-
tributable to the
vaccine
Rowland 2013
NCT00548444
ID 2007-10 MVA85A; 1
dose
(1 x 10
8 PFU), ad-
ministered as
2 injec-
tions (5 x 107
PFU each in-
jection)
UK 12 adults -ve 7 trials (112 par-
ticipants)
; data combined
in one report: no
serious AE at-
tributable to the
vaccine
Porter (unpub-
lished data:
source Rowland
2012)
NCT00731471
ID 2008-11 MVA85A; 2
doses (spaced
by 6 to 12
months) (1 x
108 PFU)
Senegal 24 adults +ve No serious AE at-
tributable to the
vaccine
Dieye 2013
NCT01181856
ID
IM
2010-1 MVA85A; 1
dose (1 x 108
PFU)
UK 24 adults -ve No serious AE at-
tributable to the
vaccine
Matsumiya
2013; Meyer
2013
NCT01194180
ID 2010-2 MVA85A,
BCG;
1 dose (1 x 10
8 PFU)
Group A:
BCG naïve,
no MVA85A
UK 49 adults re-
cruited
(48 com-
pleted study)
-ve No serious AE at-
tributable to the
vaccine
Harris 2014a;
Harris 2014b;
Matsumiya 2013
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Table 2. Summary of Phase 1 studies (Continued)
Group B:
BCG naïve,
MVA85A
Group
C: BCG vac-
cinated, no
MVA85A
Group
D: BCG vac-
cinated,
MVA85A.
NCT01497769
Aerosol
ID
2011-3 MVA85A; 1
dose: 1 x 108,
1 x 107PFU
UK 24 adults -ve No vaccine re-
lated serious ad-
verse effects.
Satti 2014
NCT01683773
ID 2012-4 AERAS-402
MVA85A;
Group A: 2
doses
AERAS-402
then
MVA85A
Group B: 1
dose
AERAS-402
then
MVA85A
UK 40 adults -ve No vaccine re-
lated serious ad-
verse effects
Sheehan 2015
NCT01879163
ID 2013-4 MVA85A
IMX313;
GroupA: low
dose
MVA85A-
IMX313 (1 x
107 PFU)
Group B:
dose
MVA85A-
IMX313 (5 x
107 PFU)
Group C:
MVA85A (5
x 107 PFU)
UK 30 BCG vac-
cinated
adults
-ve No vaccine re-
lated serious AE
Minhinnick
2016
NCT01829490
IM 2013-6 MVA85A,
ChAdOx1
85A;
Group A:
1 dose ChA-
UK 42 adults -ve No data reported
yet
No publication
NCT01829490
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Table 2. Summary of Phase 1 studies (Continued)
dOx1 85A
Group B:
1 dose ChA-
dOx1 85A
then
MVA85A
Group C: 2
doses ChA-
dOx1 85A
then
MVA85A (1
x 108 PFU)
NCT01954563
Aerosol
ID
2013-6 MVA85A;
Group 1:
aerosol then
ID
Group 2: ID
then aerosol
Group 3: ID
then ID (5 x
107 PFU)
UK 37 adults -ve No data reported
yet
Manjaly Thomas
2016
(conference
abstract)
NCT02532036
Aerosol
ID
2015-8 MVA85A; 1
x 107
PFU aerosol
inhaled,
5 x 10
7 aerosol and
ID
UK 15 adults -ve No data reported
yet
NCT02532036
Abbreviations: -ve: negative; +ve: positive; intradermal: ID; intramuscular: IM; plaque-forming unit: PFU; adverse event: AE; not
reported: N/R.
Table 3. Adverse events risk of bias methods
Criterion Assessment Explanation
Patient-reported symptoms
Was monitoring active or passive? Active
Passive
Unclear
We will classify monitoring as ’active’ when authors
reviewed participants at set time points and enquired
about symptoms
Was blinding for participants and outcome
assessors adequate?
Adequate
Inadequate
Unclear
We will classify blinding as ’adequate’ when both par-
ticipants and outcome assessors were blinded to the
intervention group, and the methods of blinding (in-
cluding use of a placebo) were described
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Table 3. Adverse events risk of bias methods (Continued)
Was outcome data reporting complete or
incomplete?
Complete
Incomplete
Unclear
We will classify outcome data reporting as ’complete’
when data was presented for all the time-points where
it was collected
Were all participants included in reporting? Yes
No
We will report the percentage of randomised partici-
pants included in adverse event reporting
Was the analysis independent of study
sponsor?
Yes
No
Unclear
We will classify the analysis of trials sponsored by phar-
maceutical companies as independent of the sponsor
when it was clearly stated that the sponsor had no in-
put to the trial analysis
Laboratory tests
Number of tests undertaken - We will extract the type and number of laboratory tests
were taken
Timing of tests: was number and timing of
tests adequate?
Adequate
Inadequate
We will classify the number and timing of tests as ’ad-
equate’, when tests were taken at baseline, plus two
other time points within the first week after treatment,
plus the last day of the study. We will class the number
of test taken as “inadequate”, if either the laboratory
controls in the first week or controls at four weeks were
not performed
Reporting of test results: was reporting of
test results complete?
Complete
Incomplete
We will classify reporting as ’complete’ when test re-
sults of all time points were reported. For the trials
with inadequate number of tests taken, we will con-
sider completeness of reporting as inconsequential, and
therefore did not record a judgement
Independence of data analysis: was data
analysis independent?
Yes
No
Unclear
We will classify the analysis of trials sponsored by phar-
maceutical companies as independent of the sponsor
when it is clearly stated that the sponsor had no input
to the trial analysis
Adapted from Bukirwa 2014.
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A P P E N D I C E S
Appendix 1. Sample MEDLINE (PubMed) search terms
#7 Search #3 and #6¹
#6 Search 4 or 5
#5 “antigen 85A” OR Ag85A OR “modified vaccinia ankara” OR MVA85A Field: Title/Abstract
#4 “antigen 85A, Mycobacterium tuberculosis” [Supplementary Concept] or “MVA 85A” [Supplementary Concept])
#3 Search 1 or 2
#2 ((“BCG Vaccine”[Mesh]) OR “bcg vaccin*” or “bacille Calmette-Guérin” Field: Title/Abstract
#1 “Tuberculosis”[Mesh] or tuberculosis or TB Field: Title/Abstract
¹We will use search terms in combination with the search strategy for retrieving trials developed by Cochrane (Lefebvre 2011).
This is the preliminary search strategy for MEDLINE (PubMed). We will adapt it for searching other electronic databases. All search
strategies will be reported in full in the final version of the review.
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